31 July 2025 - Report will be subject of CTAF meeting in February 2026; draft scoping document open to public comment until 20 August 2025.

The ICER announced today that it will assess the comparative clinical effectiveness and value of therapies targeting abnormal complexes of immunoglobulin for IgA nephropathy. These are expected to include sibeprenlimab (Otsuka), atacicept (Vera Therapeutics), and budesonide (Tarpeyo, Calliditas Therapeutics). 

Read ICER Announcement